Skip to main content
. 2021 Jan;10(1):563–580. doi: 10.21037/tlcr-20-509

Figure 2.

Figure 2

Process mapping of a patient with NSCLC. The patient’s trajectory from screening and diagnosis to post-operative course and survivorship is inevitably influenced by the treatment modalities, whether neoadjuvant or adjuvant, offered during the process itself. Neoadjuvant therapy leads to many informative and valuable opportunities for improvement, including risk factor modification, biomarker exploration, prehabilitation, nutrition optimization and scientific discovery. NSCLC, non-small cell lung cancer.